62 results on '"Adolfsson, Jan"'
Search Results
2. Modeling Disease Trajectories for Castration-resistant Prostate Cancer Using Nationwide Population-based Data
3. The STHLM3-model, Risk-based Prostate Cancer Testing Identifies Men at High Risk Without Inducing Negative Psychosocial Effects
4. Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received
5. The Impact of Design and Performance in Prostate-Specific Antigen Screening: Differences Between ERSPC Centers
6. Poor Follow-up After Elevated Prostate-specific Antigen Tests: A Population-based Cohort Study
7. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer
8. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging
9. The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50–69 yr Compared with Current Prostate Cancer Testing
10. Balancing Overdiagnosis and Early Detection of Prostate Cancer using the Stockholm-3 Model
11. Prostate Cancer Death After Radiotherapy or Radical Prostatectomy: A Nationwide Population-based Observational Study
12. The use of palliative medications before death from prostate cancer: Swedish population-based study with a comparative overview of European data
13. Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based Study
14. Detection of Prostate Cancer Using a Multistep Approach with Prostate-specific Antigen, the Stockholm 3 Test, and Targeted Biopsies: The STHLM3 MRI Project
15. Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate Cancer
16. Prostate Cancer Radiation Therapy and Risk of Thromboembolic Events
17. Re: Adi J. Klil-Drori, Hui Yin, Vicky Tagalakis, Armen Aprikian, Laurent Azoulay. Androgen Deprivation Therapy for Prostate Cancer and Risk of Venous Thromboembolism. Eur Urol 2016;70:56–61
18. Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study
19. Quantifying Observational Evidence for Risk of Fatal and Nonfatal Cardiovascular Disease Following Androgen Deprivation Therapy for Prostate Cancer: A Meta-analysis
20. The risk of prostate cancer for men on aspirin, statin or antidiabetic medications
21. Patterns of androgen deprivation therapies among men diagnosed with localised prostate cancer: A population-based study
22. A Population-based Assessment of Germline HOXB13 G84E Mutation and Prostate Cancer Risk
23. Risk of suicide in men with low-risk prostate cancer
24. Differences in survival from prostate cancer in Denmark, Iceland and Sweden
25. Reply from Authors re: Goutham Vemana, Gerald L. Andriole. Bad Habits May Be Hard to Break. Eur Urol 2013;63:426–7
26. Prostate-specific Antigen (PSA) Testing Is Prevalent and Increasing in Stockholm County, Sweden, Despite No Recommendations for PSA Screening: Results from a Population-based Study, 2003–2011
27. Thromboembolic Events Following Surgery for Prostate Cancer
28. Concordance of Tumor Differentiation Among Brothers with Prostate Cancer
29. Incidence of fractures causing hospitalisation in prostate cancer patients: Results from the population-based PCBaSe Sweden
30. Reply to Tommaso Cai, Carolina D’Elia, and Beatrice Detti's Letter to the Editor re: Mieke Van Hemelrijck, Hans Garmo, Lars Holmberg, et al. Multiple Events of Fractures and Cardiovascular and Thromboembolic Disease Following Prostate Cancer Diagnosis: Results From the Population-Based PCBaSe Sweden. Eur Urol 2012;61:690–700
31. Reply from Authors re: Matthew R. Cooperberg. Adverse Effects of Androgen Deprivation and the Limits of National Tumor Registries. Eur Urol 2012;61:701–3
32. Differences according to socioeconomic status in the management and mortality in men with high risk prostate cancer
33. Psychiatric treatment in men with prostate cancer – Results from a Nation-wide, population-based cohort study from PCBaSe Sweden
34. Mortality Among Men with Locally Advanced Prostate Cancer Managed with Noncurative Intent: A Nationwide Study in PCBaSe Sweden
35. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden
36. Polygenic Risk Score Improves Prostate Cancer Risk Prediction: Results from the Stockholm-1 Cohort Study
37. Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden
38. Suicide Risk in Men with Prostate-Specific Antigen–Detected Early Prostate Cancer: A Nationwide Population-Based Cohort Study from PCBaSe Sweden
39. Alcohol influence on acrylamide to glycidamide metabolism assessed with hemoglobin-adducts and questionnaire data
40. Development of a New Method for Monitoring Prostate-Specific Antigen Changes in Men with Localised Prostate Cancer: A Comparison of Observational Cohorts
41. Editorial Comment on: Pharmacological Approaches to Reducing the Risk of Prostate Cancer
42. Re: Parenteral Estrogen versus Combined Androgen Deprivation in the Treatment of Metastatic Prostatic Cancer: Part 2. Final Evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5
43. Editorial Comment on: Predicting the Probability of Deferred Radical Treatment for Localised Prostate Cancer Managed by Active Surveillance
44. The Management of Category T1a–T1b (Incidental) Prostate Cancer: Can We Predict Who Needs Treatment?
45. Predictors for the symptomatic prostate cancer patient’s delays in seeking care
46. The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic Value of Tumour Ploidy and Comorbidity
47. The Choice Between a Therapy-Induced Long-Term Symptom and Shortened Survival Due to Prostate Cancer
48. Castration and osteoporisrelated fractures in a 30-year follow-up
49. Predisone has quality-of-life benefits over flutamide in the treatment of hormone-resistant prostate cancer
50. Active Monitoring (Deferred Treatment or Watchful Waiting) in the Treatment of Prostate Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.